EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
The efficacy of CAR-T cells for solid tumors is unsatisfactory. EpCAM is a biomarker of epithelial tumors, but the clinical feasibility of CAR-T therapy targeting EpCAM is lacking. Here, we report pre- and clinical investigations of EpCAM–CAR-T cells for solid tumors. We demonstrated that EpCAM–CAR-T cells costimulated by Dectin-1 exhibited robust antitumor activity without adverse effects in xenograft mouse models and EpCAM-humanized mice. Notably, in clinical trials for epithelial tumors (NCT02915445), 6 (50%) of the 12 enrolled patients experienced self-remitted grade 1/2 toxicities, 1 patient (8.3%) experienced reversible grade 3 leukopenia, and no higher-grade toxicity reported. Efficacy analysis determined two patients as partial response. Three patients showed >23 months of progression-free survival, among whom one patient experienced 2-year progress-free survival with detectable CAR-T cells 200 days after infusion. These data demonstrate the feasibility and tolerability of EpCAM–CAR-T therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CAR-T cells currently under development for targeting colorectal CSCs include CD133-, EpCAM-, or CD166-directed CAR-T cells [229,230,231,232].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [231]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“The robust release of inflammatory cytokines and the proliferation of CAR-T cells contribute to antitumor efficacy in the treat-ment of hematological malignancies ( 54 ).”
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · cited 2×
“5, A to D), there was no treatment-related CRS in any of the patients as evaluated by former reported CRS diagnosis criteria ( 36 ).”
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533 · cited 2×
“However, potential antigens targeted by CAR-T therapy are not restricted to tumor cells, and they are also expressed on normal tissues, leading to lethal on-target/off-tumor toxicity to normal tissues ( 5 , 6 ).”
Self-citationCirculating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Yu, M., Bardia, A., Wittner, B. S., Stott, S. L., Smas, M. E., Ting, D. T., Isakoff, S. J., Ciciliano, J. C., Wells, M. N., Shah, A. M., et al. (2013) · Science · doi:10.1126/science.1228522 · Cited by 2,476 · cited 1×
“…EpCAM was expressed on cancer stem cells and circulating tumor cells (CTCs) and was closely associated with tumor recurrence and metastasis ( 11 , 12 ), leading to the approval of EpCAM by the Food and Drug Administration as a diagnostic marker of CTCs of breast, prostate, and colorectal cancers…”
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438 · cited 1×
“Cytokine release syndrome (CRS) is a critical clinical sign of excessive T cell activation and proinflammatory cytokine production and is a key predictor of fatal adverse events in T cell therapy ( 33 ).”
A human memory T cell subset with stem cell–like properties
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974 · cited 1×
“Previous research demonstrated that a memory phenotype is preferable to terminal differentiated effectors in adoptive therapy due to superior proliferation and persistence ( 31 ).”
Cited by
Understanding and overcoming multidrug resistance in cancer
Ge, M., Chen, X.-Y., Huang, P., Fleishman, J. S., Yang, D., Wu, Z., Ke, Z., & Chen, Z. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01059-1 · Cited by 167
“…a phase I trial evaluating CAR T cells targeting the CSC surface marker EpCAM reported manageable toxicities and durable responses in patients with advanced-stage EpCAM + epithelial tumours, with 2 of 12 patients having a partial response and 3 others having stable disease for >23 months 315 .”
Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control
Lu, L., Xie, M., Yang, B., Zhao, W., & Cao, J. (2024) · Science Advances · doi:10.1126/sciadv.adj6251 · Cited by 129
Viral oncogenesis in cancer: from mechanisms to therapeutics
Xiao, Q., Liu, Y., Li, T., Wang, C., He, S., Zhai, L., Yang, Z., Zhang, X., Wu, Y., & Liu, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02197-9 · Cited by 128
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
Khan, S. H., Choi, Y., Veena, M. S., Lee, J. K., & Shin, D. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1489827 · Cited by 96
“A CAR T cell trial targeting epithelial cell adhesion molecule (EpCAM) is ongoing now (NCT02915445) (167).”
Metadata
- Authors
- Li, D., Guo, X., Yang, K., Yang, Y., Zhou, W., Huang, Y., Liang, X., Su, J., Jiang, L., Li, J., Fu, M., He, H., Yang, J., Shi, H., Yang, H., Tong, A., Chen, N., Hu, J., Xu, Q., Wei, Y.-Q., & Wang, W.
- Affiliations
- Sichuan University (CN)
- Shanghai Tenth People's Hospital (CN)
- Sun Yat-sen University (CN)
- Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China.
- Corresponding author
- Li, Dan
- Guo, Xianling
- Yang, Kun
- Chen, Nianyong
- Xu, Qing
- Wei, Yu-Quan
- Wang, Wei
- ORCID
- Venue
- Science Advances
- Published
- 2023-12
- Volume
- 9
- Issue
- 48
- Pages
- eadg9721-eadg9721
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC10691766
- OpenAlex
- W4389232854
- Cited by
- 97
- References
- 57
- Citations by year
- 2026: 31 · 2025: 49 · 2024: 17
- FWCI
- 11.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81972878, 82172733)
- National Key Research and Development Program of China (2016YFC1303403, 2020YFC0860200)
- Key Research and Development Program of Sichuan Province (2022ZDZX0024)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- EpCAM, CAR T-cell therapy, solid tumors, epithelial tumors, antitumor immunity, xenograft models, humanized mice, treatment toxicity, progression-free survival, tumor markers
- MeSH terms
- Epithelial Cell Adhesion Molecule, Receptors, Chimeric Antigen, Animals, Humans, Immunotherapy, Neoplasms, Glandular and Epithelial, T-Lymphocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors. https://app.cochat.ai/papers/10.1126/sciadv.adg9721
- The paper
- Li, D., Guo, X., Yang, K., Yang, Y., Zhou, W., Huang, Y., Liang, X., Su, J., Jiang, L., Li, J., Fu, M., He, H., Yang, J., Shi, H., Yang, H., Tong, A., Chen, N., Hu, J., Xu, Q., . . . Wang, W. (2023). EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors. Science Advances. https://doi.org/10.1126/sciadv.adg9721
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.